Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

BACKGROUND: Alectinib is an oral drug developed for the treatment of patients with fusion gene encoding echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-rearranged non-small cell lung cancer (NSCLC). Here, we present the case of a patient treated with alectinib...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Case Rep Oncol
Hlavní autoři: Kimura, Tatsuo, Sowa-Osako, Junko, Nakai, Toshiyuki, Ohyama, Ayako, Kawaguchi, Tomoya, Tsuruta, Daisuke, Ohsawa, Masahiko, Hirata, Kazuto
Médium: Artigo
Jazyk:Inglês
Vydáno: S. Karger AG 2016
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216233/
https://ncbi.nlm.nih.gov/pubmed/28101031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000453314
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky